Bionormanas - Company finances
|
EUR
|
2019
From: 2019-01-01
To: 2019-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 192,153 | 244,945 | 229,816 | 42,366 | 21,578 |
| Profit before tax | 508 | 12,128 | - | - | - |
| Net profit | 408 | 11,469 | -12,367 | -5,145 | -1,055 |
| Equity | 58,805 | 25 | -12,341 | -17,486 | -18,542 |
| Liabilities | - | 112,354 | 120,356 | 117,091 | 104,132 |
| Non-current assets | 86,314 | 101,722 | 92,825 | 84,263 | 75,711 |
| Current assets | 12,162 | 10,657 | 15,190 | 15,342 | 9,879 |
| Total assets | 98,476 | 112,379 | 108,015 | 99,605 | 85,590 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 12,070 | 6,001 | 3,982 |
| Social insurance contributions | - | - | 25,266 | 2,695 | 449 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | -6.2% | -81.6% | -49.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.4% | 10.2% | -11.4% | -5.2% | -1.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.7% | 45876.0% | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.2% | 4.7% | -5.4% | -12.1% | -4.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 0.3% | 5.0% | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 4494.2 | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 16,125 | 21,300 | 17,345 | 17,531 | 15,231 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bionormanas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-24 | 4.31 |
| 2026-04-28 | 2026-04-29 | 4.31 |
| 2026-04-26 | 2026-04-27 | 3.25 |
| 2026-04-23 | 2026-04-25 | 4.31 |
| 2026-04-20 | 2026-04-22 | 3.25 |
| 2026-03-29 | 2026-03-30 | 3.25 |
| 2026-03-17 | 2026-03-27 | 3.25 |
| 2026-02-18 | 2026-02-26 | 3.25 |
| 2026-01-21 | 2026-01-29 | 3.25 |
| 2025-11-18 | 2025-11-23 | 2.64 |
| 2025-10-23 | 2025-10-30 | 2.64 |
| 2025-08-28 | 2025-08-29 | 2.88 |
| 2025-08-19 | 2025-08-26 | 2.88 |
| 2025-07-24 | 2025-07-30 | 2.87 |
| 2025-05-16 | 2025-05-18 | 2.97 |
| 2025-04-24 | 2025-04-28 | 2.97 |
| 2025-02-18 | 2025-02-20 | 1.16 |
| 2025-02-10 | 2025-02-10 | 1.16 |
| 2025-01-22 | 2025-01-30 | 1.16 |
| 2024-05-16 | 2024-05-30 | 2.37 |
| 2024-04-23 | 2024-04-29 | 2.37 |
| 2024-02-19 | 2024-02-21 | 3.70 |
| 2024-01-23 | 2024-02-13 | 3.70 |
| 2024-01-16 | 2024-01-22 | 0.06 |
| 2023-12-22 | 2024-01-09 | 0.06 |
| 2023-12-18 | 2023-12-21 | 2.88 |
| 2023-03-16 | 2023-03-20 | 11.46 |
| 2022-09-16 | 2022-09-19 | 0.03 |
| 2022-07-25 | 2022-08-11 | 5.39 |
| 2022-06-16 | 2022-06-19 | 971.36 |
| 2022-05-18 | 2022-05-23 | 1893.64 |
| 2022-05-17 | 2022-05-17 | 1927.41 |
| 2022-04-26 | 2022-05-16 | 33.77 |
| 2022-04-25 | 2022-04-25 | 493.95 |
| 2022-04-19 | 2022-04-24 | 482.81 |
| 2022-03-16 | 2022-04-10 | 1366.38 |
| 2021-12-16 | 2021-12-20 | 1507.54 |
| 2021-11-16 | 2021-11-21 | 1549.99 |
Bionormanas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bionormanas, UAB (code 303084088) is a Private Limited Liability Company engaged in restaurant activities. In 2025, the company generated EUR 21.6K in revenue and posted a net loss of EUR 1.1K, corresponding to a negative profit margin of 4.9%. Performance weakened materially over the three-year period: revenue fell from EUR 229.8K in 2023 to EUR 42.4K in 2024 and then to EUR 21.6K in 2025, while losses narrowed from EUR 12.4K in 2023 to EUR 5.1K in 2024 and EUR 1.1K in 2025. The balance sheet also contracted, with total assets decreasing from EUR 108.0K in 2023 to EUR 85.6K in 2025. Equity remained negative at EUR 18.5K in 2025, while liabilities stood at EUR 104.1K. Long-term assets were EUR 75.7K and short-term assets EUR 9.9K. Asset turnover was 0.25x, indicating limited revenue generation relative to asset size. Revenue per employee was EUR 21.6K and profit per employee was negative, reflecting continued operating pressure despite a smaller loss than in prior years.